Tailin Bio has released its 2026 interim report. The company's total operating revenue was 165 million yuan, net profit attributable to the parent company was 20.3728 million yuan, and net cash inflow from operating activities was 21.1006 million yuan. The company's latest asset-liability ratio was 15.68 percent, up 0.85 percentage points from the previous quarter and up 3.10 percentage points from the same period last year. Gross margin was 49.02 percent, down 1.29 percentage points from the previous quarter and down 2.91 percentage points from the same period last year. Return on equity was 2.58 percent. Diluted earnings per share were 0.17 yuan, total asset turnover was 0.17 times, and inventory turnover was 0.64 times. The number of shareholders was 10,900, and the top ten shareholders held 62.36 percent of the total share capital.
Zhejiang Tailin Bioengineering Co LtdInterim report shows net profit of 20.37M yuan but gross margin and asset-liability ratio deteriorated, giving mixed signals.